Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

  • 1

    ObergKHellmanPKwekkeboomDJelicS. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2010;21(Suppl 5):v220222.

    • Search Google Scholar
    • Export Citation
  • 2

    GovindanRPageNMorgenszternD. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol2006;24:45394544.

    • Search Google Scholar
    • Export Citation
  • 3

    NavadaSLaiPSchwartzAKalemkerianG. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database [abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 7082.

    • Search Google Scholar
    • Export Citation
  • 4

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 5

    MurrayNTurrisiATIII. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol2006;1:270278.

  • 6

    HannCLRudinCM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park)2008;22:14861492.

    • Search Google Scholar
    • Export Citation
  • 7

    JohnsonBEJannePA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am2004;18:309322.

    • Search Google Scholar
    • Export Citation
  • 8

    DemedtsIKVermaelenKYvan MeerbeeckJP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J2010;35:202215.

    • Search Google Scholar
    • Export Citation
  • 9

    VideticGMStittLWDarAR. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol2003;21:15441549.

    • Search Google Scholar
    • Export Citation
  • 10

    ZakowskiMF. Pathology of small cell carcinoma of the lung. Semin Oncol2003;30:38.

  • 11

    BrennerBTangLHKlimstraDSKelsenDP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol2004;22:27302739.

  • 12

    GalanisEFrytakSLloydRV. Extrapulmonary small cell carcinoma. Cancer1997;79:17291736.

  • 13

    RemickSCRuckdeschelJC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol1992;20:8999.

    • Search Google Scholar
    • Export Citation
  • 14

    JohnsonBEWhang-PengJNaylorSL. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer Inst1989;81:12231228.

    • Search Google Scholar
    • Export Citation
  • 15

    GuineeDGJrFishbackNFKossMN. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol1994;102:406414.

    • Search Google Scholar
    • Export Citation
  • 16

    TravisWD. Advances in neuroendocrine lung tumors. Ann Oncol2010;21(Suppl 7):vii6571.

  • 17

    GustafssonBIKiddMChanA. Bronchopulmonary neuroendocrine tumors. Cancer2008;113:521.

  • 18

    RenshawAAHajaJLozanoRLWilburDC. Distinguishing carcinoid tumor from small cell carcinoma of the lung: correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. Arch Pathol Lab Med2005;129:614618.

    • Search Google Scholar
    • Export Citation
  • 19

    AberleDRAdamsAMBergCD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med2011;365:395409.

  • 20

    CuffeSMouaTSummerfieldR. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol2011;6:818822.

    • Search Google Scholar
    • Export Citation
  • 21

    GandhiLJohnsonBE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw2006;4:631638.

  • 22

    KazarianMLaird-OffringaIA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer2011;10:33.

    • Search Google Scholar
    • Export Citation
  • 23

    MarchioliCCGrazianoSL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin N Am1997;7:6580.

  • 24

    TitulaerMJWirtzPWWillemsLN. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol2008;26:42764281.

    • Search Google Scholar
    • Export Citation
  • 25

    MerineySDHulsizerSCLennonVAGrinnellAD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol1996;40:739749.

    • Search Google Scholar
    • Export Citation
  • 26

    GrausFKeime-GuibertFReneR. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain2001;124:11381148.

  • 27

    DelisleLBoyerMJWarrD. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med1993;153:746752.

    • Search Google Scholar
    • Export Citation
  • 28

    JohnsonBEChuteJPRushinJ. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med1997;156:16691678.

    • Search Google Scholar
    • Export Citation
  • 29

    CastilloJJVincentMJusticeE. Diagnosis and management of hyponatremia in cancer patients. Oncologist2012;17:756765.

  • 30

    PelosofLCGerberDE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc2010;85:838854.

  • 31

    SchrierRWGrossPGheorghiadeM. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med2006;355:20992112.

    • Search Google Scholar
    • Export Citation
  • 32

    VerbalisJGZeltserDSmithN. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf)2008;69:159168.

    • Search Google Scholar
    • Export Citation
  • 33

    MickePFaldumAMetzT. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?Lung Cancer2002;37:271276.

    • Search Google Scholar
    • Export Citation
  • 34

    KalemkerianGP. Staging and imaging of small cell lung cancer. Cancer Imaging2011;11:253258.

  • 35

    ShepherdFACrowleyJVan HoutteP. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol2007;2:10671077.

    • Search Google Scholar
    • Export Citation
  • 36

    Ignatius OuSHZellJA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol2009;4:300310.

    • Search Google Scholar
    • Export Citation
  • 37

    VallieresEShepherdFACrowleyJ. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol2009;4:10491059.

    • Search Google Scholar
    • Export Citation
  • 38

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual7th ed.New York, NY: Springer; 2010.

  • 39

    GoldstrawPCrowleyJChanskyK. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol2007;2:706714.

    • Search Google Scholar
    • Export Citation
  • 40

    PodoloffDABallDWBen-JosefE. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw2009;7(Suppl 2):S126.

    • Search Google Scholar
    • Export Citation
  • 41

    BradleyJDDehdashtiFMintunMA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol2004;22:32483254.

    • Search Google Scholar
    • Export Citation
  • 42

    KutVSpiesWSpiesS. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol2007;30:4550.

    • Search Google Scholar
    • Export Citation
  • 43

    AzadAChionhFScottAM. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol2010;12:443451.

    • Search Google Scholar
    • Export Citation
  • 44

    FischerBMMortensenJLangerSW. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol2007;18:338345.

    • Search Google Scholar
    • Export Citation
  • 45

    BrinkISchumacherTMixM. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging2004;31:16141620.

    • Search Google Scholar
    • Export Citation
  • 46

    KamelEMZwahlenDWyssMT. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med2003;44:19111917.

    • Search Google Scholar
    • Export Citation
  • 47

    VinjamuriMCraigMCampbell-FontaineA. Can positron emission tomography be used as a staging tool for small-cell lung cancer?Clin Lung Cancer2008;9:3034.

    • Search Google Scholar
    • Export Citation
  • 48

    FosterNRMandrekarSJSchildSE. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer2009;115:27212731.

    • Search Google Scholar
    • Export Citation
  • 49

    AlbainKSCrowleyJJLeBlancMLivingstonRB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol1990;8:15631574.

    • Search Google Scholar
    • Export Citation
  • 50

    YipDHarperPG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer2000;28:173185.

  • 51

    PostmusPEHaaxma-ReicheHGregorA. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol1998;46:2932.

    • Search Google Scholar
    • Export Citation
  • 52

    SimonMArgirisAMurrenJR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol2004;49:119133.

  • 53

    SpiraAEttingerDS. Multidisciplinary management of lung cancer. N Engl J Med2004;350:379392.

  • 54

    JohnsonBE. Management of small cell lung cancer. Clin Chest Med2002;23:225239.

  • 55

    EvansWKShepherdFAFeldR. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol1985;3:14711477.

  • 56

    JackmanDMJohnsonBE. Small-cell lung cancer. Lancet2005;366:13851396.

  • 57

    SundstromSBremnesRMKaasaS. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol2002;20:46654672.

    • Search Google Scholar
    • Export Citation
  • 58

    BishopJFRaghavanDStuart-HarrisR. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol1987;5:15741578.

    • Search Google Scholar
    • Export Citation
  • 59

    SkarlosDVSamantasEKosmidisP. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol1994;5:601607.

    • Search Google Scholar
    • Export Citation
  • 60

    OkamotoHWatanabeKKunikaneH. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer2007;97:162169.

    • Search Google Scholar
    • Export Citation
  • 61

    RossiADi MaioMChiodiniP. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol2012;30:16921698.

    • Search Google Scholar
    • Export Citation
  • 62

    NodaKNishiwakiYKawaharaM. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med2002;346:8591.

    • Search Google Scholar
    • Export Citation
  • 63

    LaraPNJrNataleRCrowleyJ. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol2009;27:25302535.

    • Search Google Scholar
    • Export Citation
  • 64

    HannaNBunnPAJrLangerC. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer 10.1200/JCO.2005.04.8595. J Clin Oncol2006;24:20382043.

    • Search Google Scholar
    • Export Citation
  • 65

    SchmittelAFischer von WeikersthalLSebastianM. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol2006;17:663667.

    • Search Google Scholar
    • Export Citation
  • 66

    HermesABergmanBBremnesR. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol2008;26:42614267.

    • Search Google Scholar
    • Export Citation
  • 67

    LimaJPdos SantosLVSasseEC. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol2010;5:19861993.

    • Search Google Scholar
    • Export Citation
  • 68

    ChuteJPChenTFeigalE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol1999;17:17941801.

    • Search Google Scholar
    • Export Citation
  • 69

    LoehrerPJSrAnsariRGoninR. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol1995;13:25942599.

    • Search Google Scholar
    • Export Citation
  • 70

    PujolJLDauresJPRiviereA. Etoposide plus cisplatin with or without the combination of 4’-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst2001;93:300308.

    • Search Google Scholar
    • Export Citation
  • 71

    MiyamotoHNakabayashiTIsobeH. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology1992;49:431435.

    • Search Google Scholar
    • Export Citation
  • 72

    NiellHBHerndonJEIIMillerAA. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol2005;23:37523759.

    • Search Google Scholar
    • Export Citation
  • 73

    SchillerJHAdakSCellaD. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol2001;19:21142122.

    • Search Google Scholar
    • Export Citation
  • 74

    GoldieJHColdmanAJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep1979;63:17271733.

    • Search Google Scholar
    • Export Citation
  • 75

    FukuokaMFuruseKSaijoN. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst1991;83:855861.

    • Search Google Scholar
    • Export Citation
  • 76

    RothBJJohnsonDHEinhornLH. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol1992;10:282291.

    • Search Google Scholar
    • Export Citation
  • 77

    MilesDWEarlHMSouhamiRL. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol1991;9:280285.

    • Search Google Scholar
    • Export Citation
  • 78

    MurrayNGelmonKShahA. Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy [abstract]. Lung Cancer1994;11(Suppl 1):99. Abstract 377.

    • Search Google Scholar
    • Export Citation
  • 79

    SculierJPPaesmansMBureauG. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol1993;11:18581865.

    • Search Google Scholar
    • Export Citation
  • 80

    SouhamiRLRuddRRuiz de ElviraMC. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol1994;12:18061813.

    • Search Google Scholar
    • Export Citation
  • 81

    FukuokaMMasudaNNegoroS. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer1997;75:306309.

    • Search Google Scholar
    • Export Citation
  • 82

    MurrayNLivingstonRBShepherdFA. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol1999;17:23002308.

    • Search Google Scholar
    • Export Citation
  • 83

    TeicherBA. Preclinical models for high-dose therapy. In: ArmitageJOAntmanKH eds. High-Dose Cancer Therapy: Pharmacology Hematopoietins Stem Cells2nd ed.Baltimore, MD: Williams and Wilkins; 1995:1442.

    • Search Google Scholar
    • Export Citation
  • 84

    CohenMHCreavenPJFossieckBEJr. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep1977;61:349354.

  • 85

    JohnsonDHEinhornLHBirchR. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol1987;5:17311738.

    • Search Google Scholar
    • Export Citation
  • 86

    IhdeDCMulshineJLKramerBS. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol1994;12:20222034.

    • Search Google Scholar
    • Export Citation
  • 87

    ArriagadaRLe ChevalierTPignonJP. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med1993;329:18481852.

    • Search Google Scholar
    • Export Citation
  • 88

    ThatcherNGirlingDJHopwoodP. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol2000;18:395404.

    • Search Google Scholar
    • Export Citation
  • 89

    KlasaRJMurrayNColdmanAJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol1991;9:499508.

    • Search Google Scholar
    • Export Citation
  • 90

    CrawfordJOzerHStollerR. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 91

    SpigelDRTownleyPMWaterhouseDM. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol2011;29:22152222.

    • Search Google Scholar
    • Export Citation
  • 92

    SpigelDRGrecoFAZubkusJD. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol2009;4:15551560.

    • Search Google Scholar
    • Export Citation
  • 93

    HornLDahlbergSESandlerAB. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group study E3501. J Clin Oncol2009;27:60066011.

    • Search Google Scholar
    • Export Citation
  • 94

    HurriaAKrisMG. Management of lung cancer in older adults. CA Cancer J Clin2003;53:325341.

  • 95

    GirlingDJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet1996;348:563566.

    • Search Google Scholar
    • Export Citation
  • 96

    SouhamiRLSpiroSGRuddRM. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst1997;89:577580.

    • Search Google Scholar
    • Export Citation
  • 97

    NeubauerMSchwartzJCaracandasJ. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with eastern cooperative oncology group performance status of 2, or age >= 70 years. J Clin Oncol2004;22:18721877.

    • Search Google Scholar
    • Export Citation
  • 98

    WesteelVMurrayNGelmonK. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol1998;16:19401947.

    • Search Google Scholar
    • Export Citation
  • 99

    OkamotoHWatanabeKNishiwakiY. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol1999;17:35403545.

    • Search Google Scholar
    • Export Citation
  • 100

    MatsuiKMasudaNYanaT. Carboplatin calculated with Chatelut’s formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med2001;40:603606.

    • Search Google Scholar
    • Export Citation
  • 101

    MurrayNGraftonCShahA. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol1998;16:33233328.

    • Search Google Scholar
    • Export Citation
  • 102

    HurwitzJLMcCoyFScullinPFennellDA. New advances in the second-line treatment of small cell lung cancer. Oncologist2009;14:986994.

  • 103

    SchneiderBJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw2008;6:323331.

  • 104

    PietanzaMCKadotaKHubermanK. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res2012;18:11381145.

    • Search Google Scholar
    • Export Citation
  • 105

    ChengSEvansWKStys-NormanDShepherdFA. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol2007;2:348354.

    • Search Google Scholar
    • Export Citation
  • 106

    EttingerDS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol2001;28:2729.

  • 107

    KellyK. New chemotherapy agents for small cell lung cancer. Chest2000;117:156S162S.

  • 108

    MastersGADeclerckLBlankeC. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group trial 1597. J Clin Oncol2003;21:15501555.

    • Search Google Scholar
    • Export Citation
  • 109

    von PawelJSchillerJHShepherdFA. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol1999;17:658667.

    • Search Google Scholar
    • Export Citation
  • 110

    O’BrienMECiuleanuTETsekovH. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol2006;24:54415447.

    • Search Google Scholar
    • Export Citation
  • 111

    EckardtJRvon PawelJPujolJL. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol2007;25:20862092.

    • Search Google Scholar
    • Export Citation
  • 112

    HuberRMReckMGosseH. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J2006;27:11831189.

    • Search Google Scholar
    • Export Citation
  • 113

    ShahCReadyNPerryM. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer2007;57:8488.

    • Search Google Scholar
    • Export Citation
  • 114

    ShipleyDLHainsworthJDSpigelDR. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)—a Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 7083.

    • Search Google Scholar
    • Export Citation
  • 115

    EttingerDSJotteRLoriganP. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol2010;28:25982603.

    • Search Google Scholar
    • Export Citation
  • 116

    InoueASugawaraSYamazakiK. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol2008;26:54015406.

    • Search Google Scholar
    • Export Citation
  • 117

    OnodaSMasudaNSetoT. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol2006;24:54485453.

    • Search Google Scholar
    • Export Citation
  • 118

    ShimokawaTShibuyaMKitamuraK. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol2009;14:6369.

    • Search Google Scholar
    • Export Citation
  • 119

    JotteRConklingPReynoldsC. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol2011;29:287293.

    • Search Google Scholar
    • Export Citation
  • 120

    BogartJAHerndonJEIILyssAP. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys2004;59:460468.

    • Search Google Scholar
    • Export Citation
  • 121

    LiengswangwongVBonnerJAShawEG. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol1994;12:496502.

    • Search Google Scholar
    • Export Citation
  • 122

    KimTHChoKHPyoHR. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology2005;235:208215.

    • Search Google Scholar
    • Export Citation
  • 123

    RoseJRodriguesGYaremkoB. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol2009;91:282287.

    • Search Google Scholar
    • Export Citation
  • 124

    KongFMRitterTQuintDJ. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys2011;81:14421457.

    • Search Google Scholar
    • Export Citation
  • 125

    ShirvaniSMKomakiRHeymachJV. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys2012;82:e9197.

    • Search Google Scholar
    • Export Citation
  • 126

    JeremicBShibamotoYNikolicN. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol1999;17:20922099.

    • Search Google Scholar
    • Export Citation
  • 127

    ArriagadaRLe ChevalierTBorieF. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst1995;87:183190.

    • Search Google Scholar
    • Export Citation
  • 128

    AuperinAArriagadaRPignonJP. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med1999;341:476484.

    • Search Google Scholar
    • Export Citation
  • 129

    SlotmanBFaivre-FinnCKramerG. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med2007;357:664672.

  • 130

    MarshJCGieldaBTHerskovicAMAbramsRA. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: current concepts and approaches. J Oncol2010;2010:198208.

    • Search Google Scholar
    • Export Citation
  • 131

    SlotmanBJSenanS. Radiotherapy in small-cell lung cancer: lessons learned and future directions. Int J Radiat Oncol Biol Phys2011;79:9981003.

    • Search Google Scholar
    • Export Citation
  • 132

    Le PechouxCDunantASenanS. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol2009;10:467474.

    • Search Google Scholar
    • Export Citation
  • 133

    WolfsonAHBaeKKomakiR. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys2011;81:7784.

    • Search Google Scholar
    • Export Citation
  • 134

    SlotmanBJMauerMEBottomleyA. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms— results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. J Clin Oncol2009;27:7884.

    • Search Google Scholar
    • Export Citation
  • 135

    MaranzanoETrippaFCasaleM. 8 Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol2009;93:174179.

    • Search Google Scholar
    • Export Citation
  • 136

    LutzSBerkLChangE. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys2011;79:965976.

    • Search Google Scholar
    • Export Citation
  • 137

    FerrellBKoczywasMGrannisFHarringtonA. Palliative care in lung cancer. Surg Clin North Am2011;91:403417.

  • 138

    TsaoMNLloydNWongRK. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev2012;4:CD003869.

    • Search Google Scholar
    • Export Citation
  • 139

    JohnsonBELinnoilaRIWilliamsJP. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol1995;13:101111.

    • Search Google Scholar
    • Export Citation
  • 140

    JohnsonBE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst1998;90:13351345.

  • 141

    RichardsonGETuckerMAVenzonDJ. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med1993;119:383390.

    • Search Google Scholar
    • Export Citation
  • 142

    KawaharaMUshijimaSKamimoriT. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer1998;78:409412.

    • Search Google Scholar
    • Export Citation
  • 143

    ParsonsADaleyABeghRAveyardP. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ2010;340:b5569.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 776 699 56
PDF Downloads 125 121 7
EPUB Downloads 0 0 0